Therapy/CAH-A

Tacrolimus Shown to Control Disease Process of a Type of Chronic Liver Disease

Published in Hepatitis Weekly, July 24th, 1995

Tacrolimus is showing promise as a potential new treatment for autoimmune chronic active hepatitis (CAH-A).

A chronic liver disease of unknown etiology, CAH-A is believed to have an autoimmune pathogenesis. The disease slowly progresses until hepatic failure and the development of portal hypertension, after which either death of liver transplantation occur. At present, the only widely recognized therapy is the administration of glucocorticoids. Glucocorticoids have both anti-inflammatory and immunosuppressive actions, and because of the psychiatric, osteoporotic and weight-enhancing actions of steroids, many patients are unable to tolerate such therapy. Other such...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (1995-07-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry